Active, not recruitingPhase 3NCT06173531

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Studying Prader-Willi syndrome

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: ACADIA Pharmaceuticals Inc.
Intervention: Carbetocin(drug)
Enrollment: 170 enrolled
Eligibility: 5-30 years · All sexes
Timeline: 2023 – 2025

Study locations (30)

Children's of Alabama, Birmingham, Alabama, United States
Phoenix Children's Hospital, Phoenix, Arizona, United States
University of California Irvine, Orange, California, United States
Stanford University School of Medicine, Palo Alto, California, United States
Rady Children's Hospital San Diego, San Diego, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
University of Iowa, Iowa City, Iowa, United States
Boston Children's Hospital, Boston, Massachusetts, United States
Children's Mercy Hospital, Kansas City, Missouri, United States
SSM Health/Saint Louis University, St Louis, Missouri, United States
Maimonides Medical Center, Brooklyn, New York, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
UPMC-Children's Hospital Pittsburgh, Pittsburgh, Pennsylvania, United States
Vanderbilt Clinical Research Center, Nashville, Tennessee, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06173531 on ClinicalTrials.gov

Other trials for Prader-Willi syndrome

Additional recruiting or active studies for the same condition.

See all trials for Prader-Willi syndrome →

← Back to all trials